[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646392":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":35,"centralContacts":43,"locations":49,"responsibleParty":117,"collaborators":35,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":35,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":35,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":52,"whyStopped":35,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Efsubaglutide Alfa 5 mg QW","EXPERIMENTAL","Efsubaglutide Alfa, 5 mg once weekly，12 weeks Solution for injection in pre-filled auto-injector pen",[13],"Drug: Efsubaglutide Alfa 5 mg QW",{"label":15,"type":10,"description":16,"interventionNames":17},"Efsubaglutide Alfa 10 mg QW","Efsubaglutide Alfa, 10 mg once weekly，12 weeks Solution for injection in pre-filled auto-injector pen",[18],"Drug: Efsubaglutide Alfa 10 mg QW",{"label":20,"type":10,"description":21,"interventionNames":22},"Efsubaglutide Alfa 20 mg QW","Efsubaglutide Alfa, 20 mg once weekly，12 weeks Solution for injection in pre-filled auto-injector pen",[23],"Drug: Efsubaglutide Alfa 20 mg QW",{"label":25,"type":26,"description":27,"interventionNames":28},"Efsubaglutide Alfa placebo","PLACEBO_COMPARATOR","Efsubaglutide Alfa placebo, once weekly，12 weeks Solution for injection in pre-filled auto-injector pen",[29],"Drug: Efsubaglutide Alfa placebo",[31,36,38,40],{"type":32,"name":9,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Efsubaglutide Alfa Injection Subcutaneous injection",[9],null,{"type":32,"name":15,"description":33,"armGroupLabels":37,"otherNames":35},[15],{"type":32,"name":20,"description":33,"armGroupLabels":39,"otherNames":35},[20],{"type":32,"name":25,"description":41,"armGroupLabels":42,"otherNames":35},"Efsubaglutide Alfa placebo Injection Subcutaneous injection",[25],[44],{"name":45,"role":46,"phone":47,"phoneExt":35,"email":48},"QINGHUA WANG, M.D,Ph.D","CONTACT","+862168788225","dr.qwang@innogenpharm.com",[50,66,81,93,107],{"facility":51,"status":52,"city":53,"state":54,"zip":35,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Beijing Chaoyang Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64],{"name":65,"role":46,"phone":35,"phoneExt":35,"email":35},"Guang Wang",{"facility":67,"status":68,"city":69,"state":70,"zip":35,"country":55,"countryCode":56,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Wuhan Central Hospital","NOT_YET_RECRUITING","Wuhan","Hubei",{"type":58,"coordinates":72},[73,74],114.26667,30.58333,{"lat":74,"lon":73},[77,79],{"name":78,"role":46,"phone":35,"phoneExt":35,"email":35},"Weihua Wang",{"name":80,"role":46,"phone":35,"phoneExt":35,"email":35},"Zhongjing Wang",{"facility":82,"status":68,"city":83,"state":84,"zip":35,"country":55,"countryCode":56,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Shengjing Hospital, China Medical University","Shenyang","Liaoning",{"type":58,"coordinates":86},[87,88],123.43278,41.79222,{"lat":88,"lon":87},[91],{"name":92,"role":46,"phone":35,"phoneExt":35,"email":35},"Xiaoguang Shi",{"facility":94,"status":68,"city":95,"state":96,"zip":35,"country":55,"countryCode":56,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Qilu Hospital, Shandong University","Jinan","Shandong",{"type":58,"coordinates":98},[99,100],116.99722,36.66833,{"lat":100,"lon":99},[103,105],{"name":104,"role":46,"phone":35,"phoneExt":35,"email":35},"Xinguo Hou",{"name":106,"role":46,"phone":35,"phoneExt":35,"email":35},"Shuwen Yu",{"facility":108,"status":52,"city":95,"state":96,"zip":35,"country":55,"countryCode":56,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Qilu Second Hospital, Shandong University",{"type":58,"coordinates":110},[99,100],{"lat":100,"lon":99},[113,115],{"name":114,"role":46,"phone":35,"phoneExt":35,"email":35},"Shuang Liang",{"name":116,"role":46,"phone":35,"phoneExt":35,"email":35},"Deqing Sun",{"type":118,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100646392","phase-1-phase-ib-study-of-efsubaglutide-alfa-injection-in-obese-adolescents-100646392",false,"NCT07693426","Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents","A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Efsubaglutide Alfa in Chinese Adolescents With Obesity","Inclusion Criteria:\n\n* 1\\. Informed consent must be obtained from the participant's parent or legally authorized representative and assent from the adolescent participant before any study-related procedures.\n* 2\\. Adolescent participants aged ≥12 years and \\\u003C18 years (at the time of informed consent).\n* 3\\. At screening, meet the obesity criteria defined in \"WS\u002FT586-2018 Screening for Overweight and Obesity among School-age Children and Adolescents\".\n* 4\\. Before screening, have been on dietary and exercise control alone for at least 3 months with \\\u003C5.0% reduction in body mass index (based on self-report or report by parent or legally authorized representative).\n* 5.Must be willing to follow the diet and exercise guidance and able to maintain such stable diet and exercise lifestyle during the study period.\n* 6\\. Female participants of childbearing potential must have a negative serum pregnancy test at screening.\n* 7\\. Able to understand all study procedures, willing to strictly comply with the study protocol, complete the study visits as scheduled, and finish the study.\n\nExclusion Criteria:\n\n* 1\\. Pre-pubertal participants (Tanner Stage I).\n* 2\\. History of severe allergic reactions or suspected allergy to study drug or its ingredients.\n* 3\\. Pregnant or lactating women; men or women of childbearing potential planning pregnancy or unwilling to use highly effective contraception throughout the study.\n* 4\\. Use of weight-affecting medications before screening.\n* 5\\. Known monogenic obesity, obesity caused by other diseases or medications,\n* 6\\. Previously diagnosed Type 1 diabetes, Type 2 diabetes, or special types of diabetes;\n* 7\\. history of severe hypoglycemia or recurrent symptomatic hypoglycemia (≥2 times within half a year).\n* 8\\. Clinically significant gastric emptying abnormalities, severe chronic gastrointestinal diseases, long-term use of medications directly affecting gastrointestinal motility, or gastrointestinal surgery within 6 months prior to screening, deemed unsuitable for the study by the investigator.\n* 9\\. History of malignancy within 5 years prior to screening, excluding clinically cured cervical intraepithelial neoplasia, squamous cell carcinoma, or basal cell carcinoma within 5 years.\n* 10\\. Major surgery within 6 months prior to screening, or planned surgery during the study that may affect study completion or compliance;\n* 11\\. history of bariatric surgery or planned bariatric surgery during the study (e.g., gastric bypass, gastric banding).\n* 12\\. History of acute or chronic pancreatitis, symptomatic gallbladder disease at screening, history of pancreatic injury, or other high-risk factors for pancreatitis; or amylase or lipase \\>2.0×ULN at screening.\n* 13\\. Known or suspected drug\u002Fsubstance abuse at screening; positive HBsAg;\n* 14\\. Positive HCV antibody with HCV RNA above the lower limit of detection; positive HIV antibody; positive Tp-Ab.\n* 15\\. Currently receiving or received chronic (\\>14 days) systemic glucocorticoid therapy within 3 months prior to screening, or evidence of severe active autoimmune disease that may require systemic glucocorticoid therapy within the next 12 months as judged by the investigator.\n* 16\\. History of hyperthyroidism or hypothyroidism, or TSH \\\u003C1.0×LLN, or TSH \\>1.5×ULN, or history of medullary thyroid carcinoma.\n* 17\\. Serum calcitonin ≥50 ng\u002FL (pg\u002FmL) at screening; ALT \\>3.0×ULN, or AST \\>3.0×ULN, or total bilirubin \\>2.0×ULN; eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m² at screening; fasting triglycerides ≥5.64 mmol\u002FL (500 mg\u002FdL).\n* 18\\. Blood donation and\u002For blood loss ≥400 mL or bone marrow donation within 3 months prior to screening, or presence of hemoglobinopathy, hemolytic anemia, sickle cell anemia, or hemoglobin \\\u003C118 g\u002FL (ages 12-\\\u003C13 years), \\\u003C129 g\u002FL (males ≥13 years), or \\\u003C114 g\u002FL (females ≥13 years).\n* 19\\. Participation in vaccine or medical device clinical trials within 3 months prior to screening, or any drug clinical trial within less than 3 months or 5 half-lives (whichever is longer).\n* 20\\. History of moderate to severe depression, anxiety disorder, or severe psychiatric illness.\n* 21\\. Any other condition that, in the opinion of the investigator, may affect the participant's safety or compliance with the study protocol.","ALL","12 Years","17 Years",{"count":130,"type":131},36,"ESTIMATED","INTERVENTIONAL",[134],"PHASE1","This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.",[137],"Adolescence Obesity",[139,140,141,142],"Efsubaglutide Alfa","GLP-1 receptor agonist","Adolescent Obesity","weight loss","2026-07-29",{"date":145,"type":146},"2026-07-30","ACTUAL",{"date":148,"type":146},"2026-07-16",{"date":150,"type":131},"2027-08-31",{"name":5,"class":6},5]